IL‐2Rα is a potential biomarker for heart failure diagnosis of patients with end‐stage renal disease and haemodialysis
Abstract Aims Heart failure (HF) is a leading cause of mortality in patients with end‐stage renal disease (ESRD) undergoing haemodialysis. Identifying novel predictors of HF is essential for improving diagnostic precision and enhancing patient outcomes. Methods This study included 68 participants fr...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-02-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.15051 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850186436118052864 |
|---|---|
| author | Bingya Lv Zhe Wang Ya Suo Shuai Shao Meng Yuan Yue Zhang Lihua Wang Guangping Li Qiankun Bao |
| author_facet | Bingya Lv Zhe Wang Ya Suo Shuai Shao Meng Yuan Yue Zhang Lihua Wang Guangping Li Qiankun Bao |
| author_sort | Bingya Lv |
| collection | DOAJ |
| description | Abstract Aims Heart failure (HF) is a leading cause of mortality in patients with end‐stage renal disease (ESRD) undergoing haemodialysis. Identifying novel predictors of HF is essential for improving diagnostic precision and enhancing patient outcomes. Methods This study included 68 participants from the Haemodialysis Centre at the Second Hospital of Tianjin Medical University. Clinical characteristics and echocardiographic data were collected and analysed. We measured the plasma of 44 cytokines to investigate their correlation with cardiac function and their potential as HF biomarkers. Results In the HF with reduced ejection fraction (HFrEF) group, the levels of several cytokines, including stem cell growth factor‐β (SCGF‐β), C–X–C motif chemokine 10 (CXCL10), interleukin‐1α (IL‐1α), interleukin‐6 (IL‐6), interleukin‐8 (IL‐8), interleukin‐16 (IL‐16), interleukin‐1 receptor antagonist protein (IL‐1Ra), interferon‐γ (IFN‐γ), tumour necrosis factor‐α (TNF‐α), leukaemia inhibitory factor (LIF), C–C motif chemokine 3 (CCL3), interleukin‐10 (IL‐10), interleukin‐2 receptor subunit alpha (IL‐2Rα), tumour necrosis factor ligand superfamily member 10 (TNFSF10), macrophage colony‐stimulating factor (M‐CSF), granulocyte colony‐stimulating factor (G‐CSF) and stem cell factor (SCF), were significantly increased, while C–C motif chemokine 11 (CCL11)/eotaxin levels were decreased compared with those in the control group (P < 0.05). Receiver operating characteristic (ROC) curve analysis highlighted TNF‐α [area under the ROC curve (AUC) = 0.85, odds ratio (OR) = 1.080, 95% confidence interval (CI): 1.033–1.128, P = 0.001], IFN‐γ (AUC = 0.84, OR = 1.836, 95% CI: 1.289–2.615, P = 0.003) and IL‐2Rα (AUC = 0.82, OR = 1.022, 95% CI: 1.009–1.035, P = 0.001) as excellent predictors for HFrEF in haemodialysis patients with ESRD, and they outperformed soluble suppression of tumourigenicity‐2 (sST2) but slightly underperformed N‐terminal pro‐brain natriuretic peptide (NT‐proBNP). IL‐2Rα (AUC = 0.77, OR = 1.018, 95% CI: 1.007–1.030, P = 0.001) demonstrated superior diagnostic capabilities when distinguishing patients with HF with left ventricular ejection fraction (LVEF) <50% from controls. IL‐2Rα emerged as a robust biomarker for left ventricular HF, while TNF‐α (AUC = 0.89, OR = 1.140, 95% CI: 1.039–1.250, P = 0.005) showed promise in assessing HF severity in patients with ESRD. IL‐2Rα (AUC = 0.80, OR = 1.017, 95% CI: 1.007–1.027, P = 0.001) also significantly predicted right ventricular systolic dysfunction. During a median follow‐up of 14 months, 10 patients (14.7%) experienced all‐cause mortality. Multivariate Cox regression analysis confirmed that plasma IL‐2Rα was an independent predictor of all‐cause death [hazard ratio (HR): 1.010, 95% CI: 1.001–1.020, P = 0.039] after adjusting for other variables. Conclusions This study underscores the potential of IL‐2Rα as a valuable biomarker for HF diagnosis and management in haemodialysis patients with ESRD and contributes to our understanding of this high‐risk population. |
| format | Article |
| id | doaj-art-d28c34d16e8f46b082bbc2116c5b2fc8 |
| institution | OA Journals |
| issn | 2055-5822 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj-art-d28c34d16e8f46b082bbc2116c5b2fc82025-08-20T02:16:21ZengWileyESC Heart Failure2055-58222025-02-0112111813210.1002/ehf2.15051IL‐2Rα is a potential biomarker for heart failure diagnosis of patients with end‐stage renal disease and haemodialysisBingya Lv0Zhe Wang1Ya Suo2Shuai Shao3Meng Yuan4Yue Zhang5Lihua Wang6Guangping Li7Qiankun Bao8Tianjin Key Laboratory of Ionic‐Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin ChinaDepartment of Kidney Disease and Blood Purification Centre, Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin ChinaTianjin Key Laboratory of Ionic‐Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin ChinaTianjin Key Laboratory of Ionic‐Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin ChinaTianjin Key Laboratory of Ionic‐Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin ChinaTianjin Key Laboratory of Ionic‐Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin ChinaDepartment of Kidney Disease and Blood Purification Centre, Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin ChinaTianjin Key Laboratory of Ionic‐Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin ChinaTianjin Key Laboratory of Ionic‐Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin ChinaAbstract Aims Heart failure (HF) is a leading cause of mortality in patients with end‐stage renal disease (ESRD) undergoing haemodialysis. Identifying novel predictors of HF is essential for improving diagnostic precision and enhancing patient outcomes. Methods This study included 68 participants from the Haemodialysis Centre at the Second Hospital of Tianjin Medical University. Clinical characteristics and echocardiographic data were collected and analysed. We measured the plasma of 44 cytokines to investigate their correlation with cardiac function and their potential as HF biomarkers. Results In the HF with reduced ejection fraction (HFrEF) group, the levels of several cytokines, including stem cell growth factor‐β (SCGF‐β), C–X–C motif chemokine 10 (CXCL10), interleukin‐1α (IL‐1α), interleukin‐6 (IL‐6), interleukin‐8 (IL‐8), interleukin‐16 (IL‐16), interleukin‐1 receptor antagonist protein (IL‐1Ra), interferon‐γ (IFN‐γ), tumour necrosis factor‐α (TNF‐α), leukaemia inhibitory factor (LIF), C–C motif chemokine 3 (CCL3), interleukin‐10 (IL‐10), interleukin‐2 receptor subunit alpha (IL‐2Rα), tumour necrosis factor ligand superfamily member 10 (TNFSF10), macrophage colony‐stimulating factor (M‐CSF), granulocyte colony‐stimulating factor (G‐CSF) and stem cell factor (SCF), were significantly increased, while C–C motif chemokine 11 (CCL11)/eotaxin levels were decreased compared with those in the control group (P < 0.05). Receiver operating characteristic (ROC) curve analysis highlighted TNF‐α [area under the ROC curve (AUC) = 0.85, odds ratio (OR) = 1.080, 95% confidence interval (CI): 1.033–1.128, P = 0.001], IFN‐γ (AUC = 0.84, OR = 1.836, 95% CI: 1.289–2.615, P = 0.003) and IL‐2Rα (AUC = 0.82, OR = 1.022, 95% CI: 1.009–1.035, P = 0.001) as excellent predictors for HFrEF in haemodialysis patients with ESRD, and they outperformed soluble suppression of tumourigenicity‐2 (sST2) but slightly underperformed N‐terminal pro‐brain natriuretic peptide (NT‐proBNP). IL‐2Rα (AUC = 0.77, OR = 1.018, 95% CI: 1.007–1.030, P = 0.001) demonstrated superior diagnostic capabilities when distinguishing patients with HF with left ventricular ejection fraction (LVEF) <50% from controls. IL‐2Rα emerged as a robust biomarker for left ventricular HF, while TNF‐α (AUC = 0.89, OR = 1.140, 95% CI: 1.039–1.250, P = 0.005) showed promise in assessing HF severity in patients with ESRD. IL‐2Rα (AUC = 0.80, OR = 1.017, 95% CI: 1.007–1.027, P = 0.001) also significantly predicted right ventricular systolic dysfunction. During a median follow‐up of 14 months, 10 patients (14.7%) experienced all‐cause mortality. Multivariate Cox regression analysis confirmed that plasma IL‐2Rα was an independent predictor of all‐cause death [hazard ratio (HR): 1.010, 95% CI: 1.001–1.020, P = 0.039] after adjusting for other variables. Conclusions This study underscores the potential of IL‐2Rα as a valuable biomarker for HF diagnosis and management in haemodialysis patients with ESRD and contributes to our understanding of this high‐risk population.https://doi.org/10.1002/ehf2.15051cytokineend‐stage renal diseaseheart failureIL‐2Rαinflammation |
| spellingShingle | Bingya Lv Zhe Wang Ya Suo Shuai Shao Meng Yuan Yue Zhang Lihua Wang Guangping Li Qiankun Bao IL‐2Rα is a potential biomarker for heart failure diagnosis of patients with end‐stage renal disease and haemodialysis ESC Heart Failure cytokine end‐stage renal disease heart failure IL‐2Rα inflammation |
| title | IL‐2Rα is a potential biomarker for heart failure diagnosis of patients with end‐stage renal disease and haemodialysis |
| title_full | IL‐2Rα is a potential biomarker for heart failure diagnosis of patients with end‐stage renal disease and haemodialysis |
| title_fullStr | IL‐2Rα is a potential biomarker for heart failure diagnosis of patients with end‐stage renal disease and haemodialysis |
| title_full_unstemmed | IL‐2Rα is a potential biomarker for heart failure diagnosis of patients with end‐stage renal disease and haemodialysis |
| title_short | IL‐2Rα is a potential biomarker for heart failure diagnosis of patients with end‐stage renal disease and haemodialysis |
| title_sort | il 2rα is a potential biomarker for heart failure diagnosis of patients with end stage renal disease and haemodialysis |
| topic | cytokine end‐stage renal disease heart failure IL‐2Rα inflammation |
| url | https://doi.org/10.1002/ehf2.15051 |
| work_keys_str_mv | AT bingyalv il2raisapotentialbiomarkerforheartfailurediagnosisofpatientswithendstagerenaldiseaseandhaemodialysis AT zhewang il2raisapotentialbiomarkerforheartfailurediagnosisofpatientswithendstagerenaldiseaseandhaemodialysis AT yasuo il2raisapotentialbiomarkerforheartfailurediagnosisofpatientswithendstagerenaldiseaseandhaemodialysis AT shuaishao il2raisapotentialbiomarkerforheartfailurediagnosisofpatientswithendstagerenaldiseaseandhaemodialysis AT mengyuan il2raisapotentialbiomarkerforheartfailurediagnosisofpatientswithendstagerenaldiseaseandhaemodialysis AT yuezhang il2raisapotentialbiomarkerforheartfailurediagnosisofpatientswithendstagerenaldiseaseandhaemodialysis AT lihuawang il2raisapotentialbiomarkerforheartfailurediagnosisofpatientswithendstagerenaldiseaseandhaemodialysis AT guangpingli il2raisapotentialbiomarkerforheartfailurediagnosisofpatientswithendstagerenaldiseaseandhaemodialysis AT qiankunbao il2raisapotentialbiomarkerforheartfailurediagnosisofpatientswithendstagerenaldiseaseandhaemodialysis |